证券代码：603259 证券简称：药明康德 公告编号：临 2026-001 无锡药明康德新药开发股份有限公司股东减持股份结果公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 公司董事会及全体董事保证公告内容与相关股东提供的信息一致。 ■ 注1：上述持股比例按照本公告日公司总股本2,983,757,155股为基础计算。 重要内容提示： ● 股东持股的基本情况 根据无锡药明康德新药开发股份有限公司（以下简称"公司"）于2025年10月30日披露的《股东减持股份 计划公告》（公告编号：临2025-070），本次减持计划实施前公司实际控制人控制的股东合计持有公司 A股股份543,364,675股，占公司总股本的18.211%。该等股份均为公司首次公开发行A股股票并上市前所 取得的股份及上市后权益分派资本公积转增股本方式取得的股份，均为无限售条件流通股。 ● 减持计划的实施结果情况 公司于2026年1月5日收到实际控制人控制的股东发出的《告知函》，截至2026年1月5日，实际控制人控 制的股东通过集中竞价和大宗交易方式累计减持公司股份59,675,143股，占公司总股本的2%。本 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 据统计，1月6日，暂无A股上市公司披露增持情况。包括恒宝股份（维权）、山外山、东方中科、盟科 药业、盛科通信、天能重工、燕东微、西部材料、蜀道装备、先锋电子、和而泰、智能自控、银邦股 份、四方精创、福莱蒽特、振华风光、麦克奥迪、农心科技、福立旺、亚威股份、浙江荣泰、宏盛股 份、同洲电子、新金路、西部黄金、金海通、和泰机电、腾景科技、神通科技、药明康德在内的30家A 股上市公司披露减持情况。 | | | 1.6上市公司盘后减持情况 | | --- | --- | --- | | 1 | 恒宝股份 | 控股股东钱京拟减持不超3%公司股份 | | 2 | 山外山 | 股东拟合计减持不超2.00%股份 | | 3 | 盟科药业 | 股东盟科香港拟减持不超3%股份 | | 4 | 东方中科 | 股东大连金投拟减持不超3.00%股份 | | 5 | 盛科通信 | 第二大股东大基金拟减持不超3%股份 | | 6 | 燕矢微 | 第四大股东大基金1月6日减持109.02万股公司股 ...

Group 1 - WuXi AppTec's third, fourth, and sixth largest shareholders reduced their holdings by 2% from November 20, 2025, to January 5, 2026, totaling 59.6751 million shares at prices ranging from 84.66 to 95.08 CNY per share [1] Group 2 - Robotech's subsidiary ficonTEC signed a significant contract worth approximately 770,000 euros (about 63.0784 million CNY) with a Swiss client, representing over 5.70% of the company's audited revenue for 2024 [2] Group 3 - Times New Material signed a sales contract for wind turbine blades worth approximately 3.32 billion CNY, effective from October 1, 2025, to December 31, 2025, which is expected to positively impact the company's performance [3] Group 4 - YHLO signed a strategic cooperation framework agreement with Brain Machine Star Chain to enhance market expansion and sales of brain-machine interface products, leveraging both companies' resources [4] Group 5 - Guanshang Technology plans to acquire 100% of Liao Jing Electronics through a combination of stock issuance and cash payment, with the deal expected to create synergies in the defense technology sector [5] Group 6 - Siwei Control announced the termination of its control change planning due to a lack of agreement on core terms, with no significant adverse impact on its business operations [6] - Baihua Pharmaceutical also terminated its control change planning for similar reasons, with no major negative effects on its operations [8] Group 7 - Chaoying Electronics adjusted the investment amount for its AI high-end printed circuit board expansion project from 1.468 billion CNY to 3.315 billion CNY, with a new production capacity target of 166,500 square meters annually [9] Group 8 - Baotailong's controlling shareholder was ordered to rectify its failure to fulfill a share buyback commitment, having only bought back 10.0018 million shares out of a planned 20 to 40 million shares [10]

Macro Dynamics - China has discovered 1,444.49 tons of gold, with plans for a new round of mineral exploration starting in 2026, aiming to enhance the exploration and development of strategic mineral resources [2] - The Ministry of Commerce emphasizes the need for a collaborative approach among government, enterprises, and consumers to promote green consumption policies effectively [3] - The 2026 National Civil Aviation Work Conference highlighted the progress in domestic aircraft development, including the certification of new models and international market expansion [4] Financial Institutions - Bank of America predicts that AI chip stocks will continue to rise, with Nvidia, Broadcom, and AMD identified as top picks as the global semiconductor market is expected to exceed $1 trillion, with a projected 30% year-on-year sales growth in 2026 [7] Market Data - The Shanghai Composite Index reached a ten-year high with a 1.5% increase, and the total trading volume in the Shanghai and Shenzhen markets exceeded 2.8 trillion yuan, marking a significant increase in market activity [8] - As of January 5, the financing balance on the Shanghai Stock Exchange was reported at 1,277.036 billion yuan, reflecting an increase of 8.24 billion yuan from the previous trading day [9] - The Hong Kong Hang Seng Index rose by 1.38%, with significant gains in the brokerage and metals sectors [10] Company Dynamics - WuXi AppTec announced that shareholders controlled by the actual controller have reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital [12] - Jia Mei Packaging's stock surged by 230% from December 17, 2025, to January 6, 2026, leading to a temporary suspension for price verification [13] - Samsung Electronics is expected to see a 160% year-on-year increase in operating profit for Q4 2025, driven by a surge in demand for storage chips due to the AI boom [14] - Alibaba's AI model for early pancreatic cancer screening has successfully identified cases that may have been missed, showcasing the potential of AI in healthcare [18] - Aerospace company Hangtian Huanyu anticipates that its commercial space revenue will account for less than 15% of total revenue in 2025, with a slight net profit growth of 0.56% year-on-year [19]

Core Viewpoint - The Medical Health Index (980016) closed at 6354.84 points, up 0.88%, with a trading volume of 29.705 billion yuan and a turnover rate of 1.0% on January 6 [1] Group 1: Index Performance - On the same day, 38 of the index's constituent stocks rose, with BGI Genomics leading with a 6.95% increase, while 11 stocks fell, with Zai Lab leading the decline at 3.72% [1] - The top ten constituent stocks of the Medical Health Index are detailed, with WuXi AppTec holding the highest weight at 10.23% and a latest price of 96.25 yuan, showing a 1.78% increase [1] Group 2: Market Capitalization - The total market capitalization of WuXi AppTec is approximately 287.187 billion yuan, while the highest market cap among the top ten is held by Hengrui Medicine at 418.542 billion yuan [1] - The market capitalization of the top ten stocks ranges from 489 million yuan for Kelun Pharmaceutical to 418.542 billion yuan for Hengrui Medicine [1] Group 3: Capital Flow - The net outflow of main funds from the constituent stocks totaled 471 million yuan, while retail investors saw a net inflow of 200 million yuan [1] - Detailed capital flow shows that WuXi AppTec had a net inflow of 180 million yuan from main funds, while Yeye Eye Care experienced a net outflow of 157 million yuan from retail investors [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 FF301 2026年1月6日 呈交日期: l. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | IRMB | | | | 本月底結存 | | | 510,476,909 RMB | | 1 RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | 股份類別 | IA | 於香港聯交所上市 ( ...

智通財經APP訊，藥明康德(02359)發佈公告，公司於2026年1月5日收到實際控制人控制的股東發出的 《告知函》，截至2026年1月5日，實際控制人控制的股東通過集中競價和大宗交易方式累計減持公司A 股股份5967.51萬股，佔公司總股本的2%。本次減持計劃已實施完畢。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2026年1月6日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2026-001 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 无锡药明康德新药开发股份有限公司 股东减持股份结果公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、 ...

从资金流向上来看，当日医疗服务板块主力资金净流出4028.92万元，游资资金净流出1.62亿元，散户资 金净流入2.02亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康德 | 1.80 Z | 4.07% | 1.01亿 | 2.28% | -2.81 Z | -6.35% | | 301293 | 三博脑科 | 9474.34万 | 31.32% | -5881.76万 | -19.44% | -3592.59万 | -11.88% | | 002173 | 创新医疗 | 7708.81万 | 56.37% | -3382.60万 | -24.74% | -4326.21万 | -31.64% | | 300015 | 爱尔眼科 | 7521.51万 | 7.12% | -1571.23万 | -1.49% | -5950.28万 | -5.63% ...

证券代码：603259 证券简称：药明康德 公告编号：临 2026-001 无锡药明康德新药开发股份有限公司 股东减持股份结果公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 公司董事会及全体董事保证公告内容与相关股东提供的信息一致。 重要内容提示： 股东持股的基本情况 根据无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日披露的《股东减持股份计划公告》（公告编号：临 2025-070），本次 减持计划实施前公司实际控制人控制的股东合计持有公司 A 股股份 543,364,675 股，占公司总股本的 18.211%。该等股份均为公司首次公开发行 A 股股票并上市 前所取得的股份及上市后权益分派资本公积转增股本方式取得的股份，均为无限 售条件流通股。 减持计划的实施结果情况 公司于 2026 年 1 月 5 日收到实际控制人控制的股东发出的《告知函》，截 至 2026 年 1 月 5 日，实际控制人控制的股东通过集中竞价和大宗交易方式累计 减持公司股份 59,675,143 股，占公司总股本的 2%。本次减持计划已实施完毕。 股东名 ...